通化金马的前世今生：2025年三季度营收8.92亿行业排52，净利润2499.14万行业排72，负债率高于行业平均

Core Viewpoint - Tonghua Jinma is a modern pharmaceutical enterprise with a significant influence in the industry, focusing on drug research, production, and sales [1] Group 1: Business Performance - In Q3 2025, Tonghua Jinma achieved a revenue of 892 million yuan, ranking 52nd among 110 companies in the industry, with the industry leader, Huadong Medicine, generating 32.664 billion yuan [2] - The net profit for the same period was 24.99 million yuan, placing the company 72nd in the industry, while the top performer, Heng Rui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Tonghua Jinma's debt-to-asset ratio was 49.17%, slightly up from 49.06% year-on-year, which is higher than the industry average of 35.26% [3] - The company's gross profit margin for Q3 2025 was 72.58%, down from 75.39% year-on-year, but still above the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman and general manager, Zhang Yufu, received a salary of 1.5014 million yuan in 2024, an increase of 601,200 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.20% to 38,200, while the average number of circulating A-shares held per shareholder increased by 3.31% to 25,300 [5]